Open AccessIngenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion
Author(s) -
Ahmed Alkhalaf,
Günther F.L. Hofbauer
Publication year - 2016
Publication title -
dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.224
H-Index - 92
eISSN - 1421-9832
pISSN - 1018-8665
DOI - 10.1159/000447391
Subject(s) - medicine , actinic keratosis , dermatology , bowen's disease , occlusion , surgery , basal cell
Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom